gastric diffuse large B-cell lymphoma

disease

On this page

Also known as primary diffuse large B-cell gastric lymphomaprimary diffuse large B-cell lymphoma of stomachprimary diffuse large B-cell lymphoma of the stomachprimary gastric diffuse large B-cell lymphoma

Summary

gastric diffuse large B-cell lymphoma (MONDO:0006223) is a cancer and 2 clinical trials. Top therapeutic interventions include rituximab. A subtype of diffuse large B-cell lymphoma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

Classification: Cancer
Clinical trials: 2

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	gastric diffuse large B-cell lymphoma
Mondo ID	MONDO:0006223
EFO	EFO:1000270
NCIT	C5253
UMLS	C1335483
MedGen	277530
GARD	0024338
Is cancer (heuristic)	yes

Also known as: gastric diffuse large B-cell lymphoma · primary diffuse large B-cell gastric lymphoma · primary diffuse large B-cell lymphoma of stomach · primary diffuse large B-cell lymphoma of the stomach · primary gastric diffuse large B-cell lymphoma

Disease family

This is a subtype of diffuse large B-cell lymphoma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › immune system disorder › leukocyte disorder › B-cell neoplasm › neoplasm of mature B-cells › diffuse large B-cell lymphoma › gastric diffuse large B-cell lymphoma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 2.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE2	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00204659	PHASE2	COMPLETED	Phase II Study With Rituximab and Cyclophosphamide, Doxorubicin, Vincristine, Prednisone (CHOP) in Patients With Gastric Diffuse Large B-Cell Non-Hodgkin’s Lymphoma
NCT02388581	PHASE2	UNKNOWN	First-line Antibiotic Therapy for Early-stage HP(+) Gastric Pure DLBCL

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
RITUXIMAB	4	1

Drugs: Rituximab